Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28316523 | 0.98 | SMN1; SMN2 (0.39) | SMN1; SMN2CA1CA2CA14ZDHHC7 | |
| Water SCHEMBL28808045 | 0.98 | SMN1; SMN2 (0.39) | SMN1; SMN2CA1CA2CA14ZDHHC7 | |
| SCHEMBL10606016 | 0.81 | CA1 (0.41) | SMN1; SMN2CA1CA2CA14ZDHHC7 | |
| SCHEMBL22169196 | 0.81 | CA1 (0.41) | SMN1; SMN2CA1CA2CA14ZDHHC7 | |
| SCHEMBL1148993 | 0.80 | SOAT1 (0.46) | MGAMGAASIMGAM2SOAT1 | |
| SCHEMBL22789677 | 0.79 | BIRC2 (0.44) | SMN1; SMN2CA14TSHRALDH1A1KMT2A | |
| SCHEMBL11631683 | 0.78 | TSHR (0.40) | SOAT1TSHRALDH1A1 | |
| SCHEMBL5143415 | 0.78 | MGAM (0.44) | SMN1; SMN2CA1CA2CA14ZDHHC7 | |
| SCHEMBL1663158 | 0.78 | SMN1; SMN2 (0.39) | SMN1; SMN2CA1CA2CA14ZDHHC7 | |
| SCHEMBL29913374 | 0.78 | SMN1; SMN2 (0.39) | SMN1; SMN2CA1CA2CA14ZDHHC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4232431-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO INC (US) | 2025-08-13 | — | — | EP | disclosed |
| CN-119528910-A | Carboxyl condensed ring derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-114773400-B | Rhodium complex, preparation method, intermediate and application thereof | 中国科学院上海有机化学研究所 | 2024-04-26 | — | — | CN | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| EP-4232431-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-116583501-A | Compounds and compositions for treating conditions associated with LPA receptor activity | 罗特斯生物公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-107417719-B | Application of titanium chelate as reaction catalyst for synthesizing benzyl carbonate or diphenyl carbonate by ester exchange | 华东理工大学 | 2022-11-25 | — | — | CN | disclosed |
| CN-114773400-A | Rhodium complex, preparation method, intermediate and application thereof | 中国科学院上海有机化学研究所 | 2022-07-22 | — | — | CN | disclosed |
| US-5726124-A | IN MIXTURE WITH OTHER HERBICIDES, ALKYLATION AND ETHERIFICATION OF PYRIMIDINONE AND THIOPYRIMIDINONE COMPOUNDS | ROHM AND HAAS COMPANY (US) | 1998-03-10 | — | — | US | disclosed |
| EP-0579424-B1 | 2-substituted pyrimidines and herbicidal use thereof | ROHM & HAAS (US) | 1996-10-23 | — | — | EP | disclosed |
| EP-0696588-A1 | 2-Arylpyrimidines and herbicidal use thereof | ROHM AND HAAS COMPANY (US) | 1996-02-14 | — | — | EP | disclosed |
| CN-1109879-A | 2-arylpyrimidines and herbicidal use thereof | ROHM & HAAS (US) | 1995-10-11 | — | — | CN | disclosed |
| US-5453414-A | 2-arylpyrimidines and herbicidal use thereof | ROHM AND HAAS COMPANY (US) | 1995-09-26 | — | — | US | disclosed |
| EP-0663396-A1 | 2-Arylpyrimidines and herbicidal use thereof | ROHM AND HAAS COMPANY (US) | 1995-07-19 | — | — | EP | disclosed |
| US-5300477-A | 2-arylpyrimidines and herbicidal use thereof | ROHM AND HAAS COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| CN-1084165-A | 2-Arylpyrimidines and weeding thereof are used | ROHM & HAAS (US) | 1994-03-23 | — | — | CN | disclosed |
| EP-0579424-A1 | 2-substituted pyrimidines and herbicidal use thereof | ROHM AND HAAS COMPANY (US) | 1994-01-19 | — | — | EP | disclosed |
| WO-1992007468-A1 | HERBICIDES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR1, LPAR2, LPAR5 | SMN1; SMN2 1526/4885CA1 3660/4885CA2 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.